Literature DB >> 7870592

Identification of two enhancer elements downstream of the human c-myc gene.

J Mautner1, S Joos, T Werner, D Eick, G W Bornkamm, A Polack.   

Abstract

Expression of the proto-oncogene c-myc is tightly regulated in vivo. Transcription of c-myc is assumed to be controlled by a number of positive and negative cis-acting control elements located upstream or within exon 1 and intron 1. However, these regulatory elements are not sufficient for c-myc expression after stable transfection or in transgenic mice. Transcription of c-myc in vivo thus requires additional control elements located outside the tested HindIII-EcoRI gene fragment. In order to identify these putative additional control elements, we mapped DNase I hypersensitive sites around the human c-myc gene in nine different tumor cell lines and in primary lymphocytes. Within the coding and 5' region of the gene, an almost identical pattern of DNase I hypersensitive sites was detected in the various cells. In contrast, chromatin analysis of the c-myc 3' region revealed a complex pattern of constitutive and tissue-specific DNase I hypersensitive sites. In enhancer trap experiments we identified two cis-acting control elements, both co-localizing with DNase I hypersensitive sites, that stimulated c-myc transcription after transient transfection in Raji or HeLa cells. Both regulatory elements exerted their enhancer activity in either orientation and regardless of their location within the plasmids. Both elements also conferred activation on a heterologous promoter. The association of these enhancers with DNase I hypersensitive sites, indicating their functional activity in vivo, make them potential candidates for the postulated regulatory control element(s) required for c-myc expression in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7870592      PMCID: PMC306632          DOI: 10.1093/nar/23.1.72

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  50 in total

1.  Chromatin structure changes suggest a compensatory response to c-myc gene amplification in malignant fibrous histiocytoma.

Authors:  J S Gibson; B P Croker
Journal:  J Cell Biochem       Date:  1992-06       Impact factor: 4.429

2.  Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc.

Authors:  S Joos; F G Haluska; M H Falk; B Henglein; H Hameister; C M Croce; G W Bornkamm
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

3.  CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA).

Authors:  J V PULVERTAFT
Journal:  Lancet       Date:  1964-02-01       Impact factor: 79.321

4.  The mouse M-lysozyme gene domain: identification of myeloid and differentiation specific DNasel hypersensitive sites and of a 3'-cis acting regulatory element.

Authors:  B Möllers; S Klages; A Wedel; M Cross; E Spooncer; T M Dexter; R Renkawitz
Journal:  Nucleic Acids Res       Date:  1992-04-25       Impact factor: 16.971

5.  A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.

Authors:  D L Bentley; M Groudine
Journal:  Nature       Date:  1986 Jun 12-18       Impact factor: 49.962

Review 6.  Nucleosome displacement in transcription.

Authors:  C C Adams; J L Workman
Journal:  Cell       Date:  1993-02-12       Impact factor: 41.582

7.  The cis-acting elements known to regulate c-myc expression ex vivo are not sufficient for correct transcription in vivo.

Authors:  A Lavenu; S Pournin; C Babinet; D Morello
Journal:  Oncogene       Date:  1994-02       Impact factor: 9.867

8.  Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.

Authors:  M Jücker; A J Roebroek; J Mautner; K Koch; D Eick; V Diehl; W J Van de Ven; H Tesch
Journal:  Oncogene       Date:  1992-05       Impact factor: 9.867

9.  Analysis of the 3' flanking region of the human c-myc gene in lymphomas with the t(8;22) and t(2;8) chromosomal translocations.

Authors:  L K Sun; L C Showe; C M Croce
Journal:  Nucleic Acids Res       Date:  1986-05-27       Impact factor: 16.971

10.  Hold back of RNA polymerase II at the transcription start site mediates down-regulation of c-myc in vivo.

Authors:  L J Strobl; D Eick
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  6 in total

1.  A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers.

Authors:  Gregory S Yochum; Colette M Sherrick; Mary Macpartlin; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

2.  Nucleosomal structures of c-myc promoters with transcriptionally engaged RNA polymerase II.

Authors:  T Albert; J Mautner; J O Funk; K Hörtnagel; A Pullner; D Eick
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

Review 3.  Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer.

Authors:  Sherri Rennoll; Gregory Yochum
Journal:  World J Biol Chem       Date:  2015-11-26

4.  A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells.

Authors:  Meera Shah; Sherri A Rennoll; Wesley M Raup-Konsavage; Gregory S Yochum
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression.

Authors:  Gregory S Yochum; Ryan Cleland; Richard H Goodman
Journal:  Mol Cell Biol       Date:  2008-10-13       Impact factor: 4.272

6.  High frequency trans-splicing in a cell line producing spliced and polyadenylated RNA polymerase I transcripts from an rDNA-myc chimeric gene.

Authors:  Célia Chen; Nicole Fossar; Dominique Weil; Marine Guillaud-Bataille; Gisèle Danglot; Brigitte Raynal; François Dautry; Alain Bernheim; Olivier Brison
Journal:  Nucleic Acids Res       Date:  2005-04-22       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.